Retatrutide
Triple GLP-1/GIP/Glucagon Agonist
Best For
Advanced metabolic protocols, visceral fat reduction, body composition optimization
24%
Body weight reduction in Phase 2 trials
3
Receptor pathways activated simultaneously
>40%
Hunger reduction in study participants
How It Works
Retatrutide is the first triple agonist — activating GLP-1, GIP, and glucagon receptors simultaneously. The glucagon receptor activation is the differentiator: it increases daily energy expenditure by stimulating hepatic fat oxidation and thermogenesis. This three-pronged approach addresses appetite, insulin sensitivity, and metabolic rate in a single molecule.
Key Research Areas
Triple Mechanism
Broadest receptor pathway activation — 3 mechanisms at once
Energy Expenditure
Enhances daily caloric burn via glucagon activation
Visceral Fat
Preferentially targets deep abdominal adipose tissue
Lean Mass
Preserves muscle during aggressive fat reduction
Research Highlights
- Broadest receptor pathway activation — 3 mechanisms at once
- Enhances daily energy expenditure and lean mass preservation
Formulation Notes
Common concentrations referenced in published clinical studies:
[NV-3020]20mg[NV-3030]30mgCategory
GLP-1, GIP, and glucagon receptor agonists represent the most significant advance in metabolic medicine. These peptides ...
Explore Lean Body category →Educational Content. This compound profile is for informational purposes only. Not intended as medical advice, diagnosis, or treatment.